You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Express Scripts

Last Updated: April 9, 2020

DrugPatentWatch Database Preview

Abbvie Inc Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Abbvie Inc
International Patents:1010
US Patents:51
Tradenames:10
Ingredients:9
NDAs:10
Drug Master File Entries: 15
Patent Litigation for Abbvie Inc: See patent lawsuits for Abbvie Inc

Drugs and US Patents for Abbvie Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 DISCN Yes No 7,148,359*PED   Start Trial   Start Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 DISCN Yes No 9,006,387   Start Trial   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-003 Apr 11, 2016 RX Yes Yes   Start Trial   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No   Start Trial   Start Trial
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No 8,492,386   Start Trial   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Abbvie Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 6,037,157*PED   Start Trial
Abbvie Inc TRICOR fenofibrate TABLET;ORAL 021203-001 Sep 4, 2001 6,277,405   Start Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 6,703,403*PED   Start Trial
Abbvie Inc TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 4,895,726   Start Trial
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 7,148,359   Start Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 7,148,359*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ABBVIE INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 145 mg ➤ Subscribe 2007-10-19
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Tablets 48 mg ➤ Subscribe 2008-07-01
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31

Supplementary Protection Certificates for Abbvie Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2340029 C 2015 019 Romania   Start Trial PRODUCT NAME: PARITAPREVIR; NATIONAL AUTHORISATION NUMBER: EU/1/14/982; DATE OF NATIONAL AUTHORISATION: 20150115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/982; DATE OF FIRST AUTHORISATION IN EEA: 20150115
2618831 300 50016-2017 Slovakia   Start Trial PRODUCT NAME: GLECAPREVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1213 20170728
2435432 C20170017 00231 Estonia   Start Trial PRODUCT NAME: VENETOKLAKS;REG NO/DATE: EU/1/16/1138 07.12.2016
2340029 1590012-9 Sweden   Start Trial PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119
2435432 C02435432/01 Switzerland   Start Trial PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66235 08.05.2018
2340029 PA2015011 Lithuania   Start Trial PRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Dow
Harvard Business School
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.